Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 20;19(11):e0311117.
doi: 10.1371/journal.pone.0311117. eCollection 2024.

Investigation of differences between chronological and vascular age in persons with multiple sclerosis

Gorica D Maric  1 , Tatjana D Pekmezovic  1 , Olivera S Tamas  2   3 , Nikola D Veselinovic  2   3 , Maja S Budimkic  2   3 , Aleksa L Jovanovic  1 , Sarlota K Mesaros  2   3 , Jelena S Drulovic  2   3
Affiliations

Investigation of differences between chronological and vascular age in persons with multiple sclerosis

Gorica D Maric et al. PLoS One. .

Abstract

Objective: To determine vascular age (VA) in a cohort of persons with multiple sclerosis (PwMS) in Belgrade, Serbia, and to assess the difference between chronological age (CA) and VA, in this population.

Material and methods: A case-control study was conducted at the Clinic of Neurology, University Clinical Center of Serbia in Belgrade. Study participants (n = 274) were recruited during regular outpatient visits. Demographic and clinical characteristics including the presence of CVD comorbidities of PwMS were collected. Data were obtained using a questionnaire, designed and adapted for the study purposes. Additionally, fasting blood samples were collected from all participants, in order to determine their lipid profile. VA was calculated based on the patient's sex, age, smoking status, total serum cholesterol level and systolic blood pressure (SBP) value. Afterwards, the study sample was divided into five groups with the different levels of the atherosclerotic burden, as follows: 1) PwMS without any CVD comorbidity; 2) PwMS with hyperlipidemia (HLP); 3) PwMS with HLP and hypertension (HTA); 4) PwMS with HLP, HTA and type 2 diabetes, and 5) PwMS with coronary artery disease (CAD). In the statistical analysis, for the determination of factors that are independently associated with the discrepancy between CA and VA in persons with MS, hierarchical regression analysis was performed.

Results: The mean values of CA and VA were statistically significantly different among the groups(p<0.001). Additionally, a significant difference was also detected between CA and VA (p<0.001). The highest VA (66.4±15.8 years) and the difference between CA and VA (6.5±7.3 years) were registered only in the group comprising PwMS, HPL, HTA and type 2 diabetes. Results of the hierarchical linear regression analysis showed that the Expanded Disability Status Scale (EDSS) score, Body mass index (BMI), physical activity and the presence of type 2 diabetes, explained a total of 24% of the variations in the difference between CA and VA, in our cohort of MS patients.

Conclusion: Our study showed significant difference between CA and VA in PwMS and additionally, increasing VA with atherosclerotic burden. Additionally, it has been demonstrated that crucial factors which led to the occurrence of these differences were BMI, physical activity, EDSS and the presence of type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Difference between vascular and chronological age in the study groups.
MS–multiple sclerosis; HLP–hyperlipidemia; HTA–hypertension; CAD–coronary artery disease.
See this image and copyright information in PMC

References

    1. MS International Federation. 3rd edition of the Atlas of MS. Available online at: https://www.atlasofms.org/map/global/epidemiology/number-of-people-with-... (Accessed September 11, 2023).
    1. Ng HS, Graf J, Zhu F, Kingwell E, Aktas O, Albrecht P, et al.. (2022) Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population. Front Immunol. 2022;12:794075. - PMC - PubMed
    1. Corboy JR, Fox RJ, Kister I, Cutter GR, Morgan CJ, Seale R, et al.. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial. Lancet Neurol. 2023;22(7):568–577. doi: 10.1016/S1474-4422(23)00154-0 - DOI - PubMed
    1. Thormann A, Sørensen PS, Koch-Henriksen N, Laursen B, Magyari M. Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality. Neurology. 2017; 89(16):1668–1675. doi: 10.1212/WNL.0000000000004508 - DOI - PubMed
    1. Magyari M, Sorensen PS. Comorbidity in multiple sclerosis. Front Neurol. 2020; 11:851. doi: 10.3389/fneur.2020.00851 - DOI - PMC - PubMed